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INTRODUCTION

1.
Tolerance is a term that has been operationally defined, as
immunological unresponsiveness to an antigen against which an
immune response would normally be mounted, and used in this
manner encompasses a variety of possible mechanisms.

One such

mechanism is carrier-induced tolerance, wrhich in the following
discussion specifically refers to tolerance induced by hapten
coupled to isologous serum proteins and is contrasted with
suppression, which induces tolerance through the mechanism of
suppressor T cells generated by presenting hapten on cell
surfaces.
In this thesis, a new model of suppression is described,
in which the concept of cell-bound hapten has been extended to
autoantigens.

Nucleosides covalently coupled to spleen cells

were used to generate suppression of anti-nucleoside antibody
production.

The data to be presented suggest that the mechanism

involves the induction of T lymphocyte mediated suppression.
This model is significant in being the first to utilize a
naturally occurring hapten and is of direct relevance to the
study of autoimmune disease, specifically systemic lupus
erythematosus (SLE) a disease whose pathology is caused by the
production of autoantibody to nucleic acids and resultant
tissue damage from immune complex deposition (88).

One of the

possibilities proposed for the pathogenesis of SLE is the loss
of suppressor cells against autoantigen resulting in autoantigen
production.

A model in which suppressor cells can be raised

against the immune response to the autoantigen, specifically

2.
nucleoside, will enable this hypothesis to be tested.

Most; ■

importantly, the generation of suppression of the antibody
response to nucleic acids might be of clinical significance in
the management and treatment of SLE.
The next section consists of a broad survey of suppressor
T cells in general followed by a more specific discussion of the
major hapten-specific suppressor systems in the literature.
The final section of this introduction is a brief description
of the rationale and objectives of this thesis project.

3.
BACKGROUND OP SUPPRESSOR T CELLS
Since the concept of suppressor lymphocyte activity was
first introduced ’oy Gershon in 1970 (1), the suppressor T cell
(T ) has been demonstrated in the regulation of nearly every
s
aspect of the immune response, and has been implicated in a wide
range of clinical disorders.

It is now well documented

that

the suppressor T cell is a distinct subset of T lymphocytes
characterized by unique, genetically determined cell surface
antigens (thy 1+ ly 2,3+ I-J+), distinguishing it from the helper
T cell (thy 1

ly 1

2,3+ I-J-) (2-4).

I-J ) and the cytotoxic T cell (thy 1
Another cell surface marker on the T

membrane appears to be a histamine receptor (9,10)-

ly

s

Suppressor

T cells are relatively more immature, functionally short-lived
and spleen seeking, whereas helper T cells are more mature,
long-lived and migrate preferentially to the lymph nodes (5,6).
The mechanism by which the T

s

mediates suppression is

still controversial although it appears that both antigenspecific and non-specific soluble "suppressor factors" are
elaborated in most suppressor systems studied.

The target

cell of suppressor factor is also controversial with data
supporting B cells (7), T cells (11) and macrophages (72).

The

best characterization of suppressor factor is by Taussig and
Holliman who recently produced a suppressor factor specific
for the antibody response to sheep erythrocytes utilizing the
technique of a hybrid T-cell line (114).

'This factor is

specific for SRBC but can also suppress the response to a hapten
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coupled to the SKBC.

The molecule is non-immunoglobulin,

composed of a large chain and a small chain in non-covalent
association with a native molecular weight of 200,000 (115)-

The

large chain binds SRBC and the small chain binds H-2 determinants
(115).
T cell mediated suppression may be classified into two
general categories: suppression induced by extrinsic antigen,
and suppression induced by autologous antigen anti-immunoglobulin
with specificity for host allotypic and idiotypic determinants
(7,8).

Extrinsically induced suppression may be either antigen

specific, affecting only the immune responses directed toward
that antigen, or non-specific, suppressing the immune responses
to multiple unrelated antigens (8).
Antigen-specific T cell suppression has been demonstrated
in a large number of immunologic phenomena: the regulation of
antibody production e.g. IgC- (11), IgE (12-14), IgM (15), ana
antibody responses under Ir gene control e.g. nonresponders to
the terpolymer antigen L-glutamic acid-L-alanine-L-tyrosine
(GAT) (16, 17, 18).

Specific suppression has been demonstrated

in low zone tolerance (19) and high zone tolerance (20).

Anti¬

gen specificity has also been found in the suppression of cellmediated immunity.

The role of T

s

in blocking the afferent

and/or efferent limb of contact sensitivity has been extensively
studied in the picryl chloride (TNCB) system (21,22,23) and
the dinitrofluorobenzene (DNFB) system (24,25,26).
experimental

These

models will be discussed in detail below.

Delayed

5.
type hypersensitivity induced by sheep erythrocytes (27), murine
lymphocytic choriomeningitis virus (28), fowl gammaglobulin (29)
and the hapten asobenzene arsonate (ABA) (30) have all been
shown to be subject to

suppression.

The graft versus host

reaction has been suppressed by Tc in several systems when the
introduction of immunocompetent cells into histoincompatible and
immunodeficient hosts is accompanied by an injection of spleen
cells or thymus cells (31,32).

Host responsiveness to various

murine tumors: methylcholanthrene-induced fibrosarcoma (33),
Walker lung carcinoma (34,35), mastocytoma (36), ultravioletinduced fibrosarcoma (37) and others (38) are suppressed by
tumor induced suppressor T cells.
T cell mediated suppression has been demonstrated to be
non-antigen specific in a variety of instances.

The phenomenon

of antigenic competition, in which the induction of an immune
response to one antigen non-specifically interferes with a
subsequent immune response to second, unrelated antigen (39),
has been shown to be thymus dependent (40).

Antigenic competi¬

tion, mediated by T , can suppress antibody responses (6),
s
prevent the development of systemic graft versus host reactions
(5), suppress allograft and tumor rejection (8), and mixed
lymphocyte reactions (4l), and can also cause acute anergy in
delayed hypersensitivity (6).

Suppressor T cells activated by

mitogens such as concanavalin A (Con A) are able to suppress
both cell mediated and humoral responses non-specifically (42-44).
Once activated, the radiosensensitive precursors of T_ become

6.
radioresistant (45).

Activation of T

s

requires protein synthesis,

oxidative phosphorylation and an intact microtubule system (46).
Non-specific Tg have also been demonstrated in spleen cells of
neonatal (approximately 14 days) and young mice, and unprimed
thymus cells (5,6).

It has become evident that the development

and expression of autoimmunity is under the regulation of non¬
antigen specific T cell suppression (6,47,48).
A number of autoimmune disorders have been studied, both
clinically and in animal and experimental models.

The classic

animal model of autoimmune disease is the New Zealand black
(NZB) mouse which develops a syndrome of autoimmune hemolytic
anemia, and glomerulonephritis closely resembling human
systemic lupus erythematosus (SLE) (49).

The Immune system of

the young NZB mice is mature compared to other strains and is
characterized by excessive antibody production to some antigens
and early loss of tolerance to foreign and self antigens (6).
Adult NZB mice have high titers of thymocytotoxic antibody (6)
and a markedly reduced population of T lymphocytes resulting
in unusual viral infections, malignancies, and decreased
capacity for tumor and graft rejection as well as decreased GVH
response.

In effect, the NZB mouse is characterized by excessive

B cell function and deficient T cell function.

A large body of

evidence suggests that the loss of suppressor T cell function
leads to the onset of the autoimmune disease: many of the T
cell defects are corrected by replenishing the adult NZB mice
with T cells from young NZB mice (47).

Neonatal thymectomy

7.
accelerates the course of autoimmune disease (6).

Infusion of

thymosin into young mice delays the appearance of autoantibodies
(50).

Other autoimmune disorders have been studied with similar

associations between the loss of T

s

and the development of

autoimmune disease: Hashimoto's thyroiditis (51,52), experimental
autoimmune encephalomyelitis (53), myasthenia gravis (54),
experimental autoimmune hemolytic anemia (55), human SLE (56,57)
and juvenile rheumatoid arthritis (58).
Whereas autoimmune disorders may in part be due to a
deficiency of T , there is now evidence that in contrast,
s
immunodeficiency disorders may be related to an abnormally high
number of T ;

common variable hypogammaglobulinemia (59),

selective IgA deficiency (59), "infectious agammaglobulinemia"
of birds (60).
The current interest in suppressor cells have resulted in
many other reports of associations between clinical syndromes
and diseases, and suppressor cells: aplastic anemia (61),
fungal infections (62), post-traumatic Immunosuppression (63),
tropical splenomegaly syndrome (64), melanoma associated immuno¬
suppression (65), inflammatory bowel disease (66), sarcoidosis
(67), diabetes (68), and pregnancy (69).
Having discussed both specific and non-specific antigen
dependent T cells mediated suppression, we now turn to T

s

suppression of antibody directed against autologous antigen anti-immunoglobulin.

These T

s

have specificity for determinants

on immunoglobulin, both allotypic (70) and idiotypic (71), and

are generated by the exposure of the animals (neonates) to anti¬
immunoglobulin specific for the host allotype or idiotype.

That

cell can suppress idiotype production is advantageous because
it allows the regulation of immune reactivity to remain even
after the antigen to which the idiotype was directed, has been
catabolized and cleared.

Idiotype specific T

can be induced

by residual antibody and the host will be able to exert negative
control on antibody production without the continued presence
of antigen (7).

HAPTEN SPECIFIC SUPPRESSOR T CELLS
Hapten-specific suppression has been investigated exten¬
sively in the picryl chloride (trinitrophenyl) system and the
DNFB (dinitrophenyl) system mentioned above as contact
sensitivity systems in which the mechanism of tolerance has been
shown to involve T

s

mediated suppression.

These systems, as well

as several others, will be presented in greater detail and com¬
pared with each'other, with regard to the following criteria:
the hapten, its characteristics and mode of presentation,
dosage requirement, the kinetics of suppression, specificity,
transfer suppression and genetic restrictions.
Hapten coupled cells were first used by Battisto and Bloom
in 1966 to induce tolerance in guinea pigs to picryl chloride
(trinitrochlorobenzene) (.31).

Intravenous injections were made

of picryl chloride coupled to syngeneic spleen cells, heatkilled spleen cells, erythrocytes and erythrocyte membranes (8l).

9.
All forms of membrane-coupled hapten suppressed development of
delayed hypersensitivity and passive cutaneous anaphylaxis anti¬
body formation (81).
The picryl chloride system was investigated further by
Asherson and Zembala.

'Their contact sensitivity system consists

of sensitizing the skin of TNCB mice with picryl chloride and
challenging 4-5 days later (22).

Tolerance is produced by

multiple i.v. injectionsof picryl sulphonic acid (PSA), a
soluble form of picryl chloride, and can be transferred by the
4^ day after sensitization (22).

The tolerance is antigen

specific, T cell dependent, and does not result in decreased
DNA synthesis or cell proliferation but seems to act on the
efferent limb of sensitization by inhibiting the expression of
immune lymph node cells.
More recently the same investigators have identified
another suppressor T cell population in the picryl chloride
system (80).

These T

s

are generated by injecting 30 x 10^

spleen cells from mice immunized with picryl chloride painting,
into normal mice which are then immunized 5 days later with
picryl chloride.

The injected T

s

were found to suppress in

vivo synthesis in the normal mice after 4 days.
differs from the T

This T„

for contact sensitivity induced by the
o

injection of picryl sulphonic acid (22) in that it did not affect
contact sensitivity, its appearance was prevented by cyclophos¬
phamide and adult thymectomy had no effect while the reverse was
true for the T

for contact sensitivity (80).
CD

10.
Greene, et al have described a different technique of
eliciting delayed type contact sensitivity reactions in mice in
the picryl chloride system, that of subcutaneous immunization of
syngeneic 3 x 10

7

TNP-modified cell or membranes followed by

challenging with picryl chloride painted on the skin (82).

This

TNP-induced contact sensitivity response was found to be T cell
dependent, could be transferred and was subject to suppression
by 5 x 10

7

spleen cells from animals which had been tolerised

g

with i.v. injection of TNP cell membrane corresponding to 10
cells (82).

The kinetics of suppression showed that i.v. treat¬

ment 5 days before subcutaneous sensitization produced maximal
suppression (82).
Scott and Long were able to demonstrate B cell tolerance
in rats that were treated intravenously with 1 x 10

7

TNP-

modified spleen cells or lymph nodes as evidenced by decreased
number of plaque-forming cells to TNP-protein conjugates (83).
Tolerance was achievable with as few as 10

S

to 10

6

TNP spleen

cells, required a latent period of 3-4 days to develop, lasted
4 weeks, and waned by 6 weeks (83)*

Injection of TNP'-modified

spleen cells also resulted in suppression of hapten delayed
hypersensitivity (83)-

Induction of tolerance required

cyclophosphamide sensitive T cells and H-2 identity was not
required (84) as contrasted with the results of Miller, et al.
(78).
Ptak and Rozycka found that i.v. injections of TNP bound
syngeneic erythrocytes or thymocytes tolerized mice to picryl

.
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chloride, abrogating contact sensitivity while leaving humoral
anti-TMP responses intact (85).

However, i.v. injections of

TNP-bound isologous IgG abrogated anti-TMP responses with no
effect on contact sensitivity to picryl chloride (85).

TNP-

bound macrophages result in suppression of both humoral and
cell-mediated responses (85).

Thus the ”split unresponsive

state” induced by TNT may be mediated by two separate mechanisms
which are triggered by different presentation modes.
The DNFB contact sensitivity system of Claman, Moorhead
and colleagues is characterized by sensitization of mice with
direct painting of the DNFB on the skin, and challenge painting
5 days later, followed by quantitation of contact sensitivity by
measurement of ear swelling 24 hours later (73)-

Tolerance is

induced 7 days before sensitization by i.v. injection of DMBSO^
(a soluble form of DNFB, DNFB bound to either intact cells
(lymphoid or erythrocytes) or cell ghosts (75)-

It was found

that the stronger the binding between the DNFB and cell membranes,
the more potent the tolerance (75)-

Moreover, intact cells were

not required, merely membrane bound DNFB (75)*

Tolerance could

be adoptively transferred to normal recipients from tolerant
donors and this transfer is T cell dependent (76).

The

tolerance induced or transferred is exquisitely specific for
DNFB (73)-

The kinetics of this system are such that the

induction of tolerance occurs within 24 hours, yet the ability
to transfer tolerance required a period of 4-7 days to develop
after i.v. induction and was lost 14 days after which the

.
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animal remained tolerant (77)-

The authors inferred that there

are two mechanisms of tolerance to DNFB: 1) a finite period of
antigen specific suppressor T cell activity which requires
several days to develop which is responsible for the transfer
of tolerance and 2) the inhibition of DNFB specific T cell clones
from receptor blockade by hapten-modified self membranes (77).
The generation of T

s

restricted (73,79)-

In this system has been shorn to be H-2
Syninduced Tg suppress the efferent limb

of contact sensitivity by blocking the expression of immune lymph
node cells (25) and alloinduced T

2

suppress the early afferent

limb of sensitization by blocking cell proliferation (26).

5
Moody, et al found that the i.v. injection of 10

TNP

coupled syngeneic mouse erythrocytes induced suppression of the
anti-DNP response to DNP-BGG (87).

Minimal suppression

occurred 7-10 days before Immunization and waned by the 17th day.
Suppression was found to be T cell dependent and hapten specific
but not exquisitely so, since TNP-induced suppression depressed
the response by a DNP immunogen.
Suppression of delayed hypersensitivity to azobenzene
arsonate (ABA) in mice has recently been demonstrated (86).
suppression was induced by the i.v. injection of 5 x 10

7

The

ABA-

modified spleen cells followed by splenectomy 7 days later and
transfer of the spleen cells into a recipient that was simultan¬
eously immunized subcutaneously with ABA-coupled spleen cells.
The suppression of DTK was found to be antigen-specific and T
cell dependent (86).

13.
RATIONALE AND OBJECTIVES OF THESIS
The various models of hapten-specific suppression described
above have been very useful in elucidating the mechanism of
suppression, but are all characterized by haptens which are
irrelevant to the immune response of naturally occurring antigens.
The model of suppression to be described in this thesis utilizes
nucleosides as the hapten.

Nucleosides, i.e. ribose (or

deoxyribose) conjugates of the purine (guanine and adenine)
and pyrrmidine (thymine and cytosine) bases of nucleic acids
were chosen because previous work by Borel and Stollar (116)
utilizing nucleoside coupled to isologous protein carriers
demonstrated nucleoside specific tolerance.

The technique

of coupling determinants larger than nucleosides such as
oligonucleotides and nucleic acids is currently being perfected,
and will be applied to the model described here for nucleosides.
It was thought that by using the techniques of coupling
nucleosides to protein devised in Borel’s nucleoside
tolerance model to similarly bind nucleosides to lymphoid cells,
it might be possible to generate a hapten-specific model of
suppression for nucleosides analogous to the models reviewed
above.

The results of this thesis show that such a model of

nucleoside suppression can indeed be generated.
The objectives of this thesis are:
(1)

to demonstrate that nucleoside-coupled lymphoid ceils can
induce T cell mediated suppression to anti-nucleoside
antibody production in vivo and in vitro.

(
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(2)

to characterize the parameters of this model, namely:
dosage requirements, kinetics and the specificity of
nucleoside suppression,

(3)

to assess the role of the cell carrier in the efficacy of
this suppression and the possibility of an H-2 requirement
for suppression,

(4)

to ascertain whether there are strain differences in
suppression and whether or not a strain resistant to
suppression exists,

(5)

and finally, to determine if suppression to nucleosides
can be induced in NZB and BWF^ mice.

MATERIALS AND METHODS

15.
ANIMALS
C57BL/6J, (C57/6J X DBA/2)F^ (hereafter referred to as
BDF^), DBA/2, BALB/c, SJL/J males were purchased from Jackson
Laboratories, Bar Harbor, Maine.

NZB males were bred from a

parental stock from the National Institute of Health, Bethesda,
ID.

Animals were fed laboratory chow.

All animals entered

experiments at ages 6 to 8 weeks unless otherwise specified.

PREPARATION OF IMMUNOGENS AND TOLEROGENS
HAPTENS
(Nucleosides)
Guanosine, adenosine and cytidine were purchased from
Sigma, St. Louis, Mo.

Thymine riboside was purchased from

Calbiochem, LaJolla, CA.

PROTEIN CARRIERS
Keyhole limpet hemocyanin ( KLH ) was obtained from
Pacific Bio Marine Supply Co., Venice, CA.
IgG2awas isolated from the serum of plamacytoma-bearing
BALB/c mice by starch block electrophoresis.
Nucleosides were conjugated to BALB/c IgG2a (RPC,-) myeloma
protein as tolerogen or to keyhole limpet hemocyanin as
immunogen by the procedure of Erlarger and Beiser (89).

A

mixture containing approximately 80 umole of each nucleoside
was oxidized with 10 ml of 0.1 M sodium periodate and added to
150 mg of IgG2a (1 umole).

After reduction with sodium

borohydride and extensive dialysis of the product, the conjugate

16.

was assayed, for protein by a microbiuret method and for nucleo¬
side content by UV spectroscopy.

The spectrum was corrected for

protein content and a millimolar extinction coefficient of 10
was used as average for the four nucleosides.

The immunogen

preparation was (AGCT)^^_^n^-KLH and G-^-KLH (the subscript
numbers indicate the total molar ratio of hapten substitution on
the carrier assuming 800,000 as the molecular weight of KLH).
Tolerogen preparation was C-^-IgGTa.

PREPARATION OF CELL SUSPENSIONS

SPLEEN CELLS (SC)
Animals were sacrificed by cervical dislocation and the
spleens were removed and homogenized together in a 15 ml glass
tissue grinder (Wheaton) in 15 ml of Minimal Eagle's Medium
(MEM), (Microbiological Associates, Walkersville, MA), washed
by centrifugation at 1000 RPM for 15 minutes three times in
50 ml MEM and once in 50 nil of a 50% solution of MEM and 0.15 M
NaHCO^ at pH 8.0.

'The cells were resuspended in 2 ml of the

50%0 MEM-NaHCO^ solution and the cell concentration determined in
a hemocytometer.
THYMUS CELLS (TC)
The thymus gland was carefully dissected from each mouse
and gently teased in MEM.

Thymus cells were then washed three

times in MEM and once in 50 ml of the 50% MEM-HCO^ solution as
with the spleen cells.

SHEEP RED BLOOD CELLS (SRBC)
SRBC's were purchased from Colorado Serum Co., Lab, Denver,
Colorado and stored at 4°C.

Prior to use in hemolytic plaque

assay or i.v. injection, SRBC's were washed three times in 0.15 M
NaHCO^..
MOUSE RED BLOOD CELLS (MRBC)
C57BL/6 males were bled under a heat lamp; blood was added
to an equal volume of Alsever's solution and stored at 4°C.

When

ready for use, MRBC were washed in 0.15 M NaHCCL three times.
Cells then counted by hemocytometer and appropriate adjustments
made in concentration.
HORSE RED BLOOD CELLS (HFBC)
HRBC's were purchased from Colorado Serum Co. Lab, Denver,
Colorado, and stored at 4°C.

Prior to use, HRBC's were washed

three times in 0.15 M NaHCO^, counted by hemocytometer and
adjusted in concentration.
NUCLEOSIDE MODIFICATION OF LYMPHOID CELLS
9
For every 10 cells, 10 mg of guanosine, or 5 mg each of
guanosine (G), adenosine (A), thymine riboside (T), and cytosine
(C) for a total of 20 mg of tetranucleoside (AGCT), were used.
Nucleoside(s) was covalently linked to cells by the method of
Stollar & Borel (90) but modified to prevent lymphoid cell lysis.
10 mg of guanosine were suspended in 3 ml of 0.15 M NaKCCL.
and then oxidized with 1.5 ml of 0.1 M sodium periodate in saline
for 20 minutes at room temperature.

Fne reaction was stopped

with 15 ul of ethylene glycol which breaks down excess periodate

13.
(89).

The cell suspension was added dropwise to the oxidized

nucleoside solution and the mixture was gently stirred at room
temperature.

The binding was stopped after 15 minutes with 100 mg

t-butylamine borane in 5 ml 0.15 M NaHCCp.

After 3 minutes at

room temperature, the reaction tube (50 ml Falcon) was filled to
50 ml with MEM and centrifuged for 15 minutes at 1000 RPM.

The

nucleoside-conjugated cells were then washed with MEM 3 more
times after which appropriate adjustments in cell concentration
were made.

Cells were then ready for intravenous injection via

tail vein.

Sham modified cells were prepared in an identical

manner except for the addition of 1.5 ml of sodium periodate
without guanosine.

Subsequent treatment with ethylene glycol,

t-butylamine borane and washings were unchanged.

Croups of 5

mice were used.
Nucleoside modification of MRBC, SRBC, and HRBC were
performed by the procedure of Stollar and Borel (90), in
essentially the same manner as above, except washes were with
0.15 M NaHCO^ buffer without added MEM, and centrifugations
were performed at 2000 RPM.
After the basic system for suppression was established (see
r

RESULTS section) with an optimal cell dose of 80 x 10° i.v. on
day 0 followed by immunization with 0.2 mg nucleoside-KLH in
Complete Freund's Adjuvant (Difco, Detroit, Mich.) and hemolytic
plaque assay on day 10, the method for binding nucleoside to
cells was reevaluated.

19.
The method described above is based on the method of
Erlarger and Beiser used to conjugate ribosides to protein (89).
The reaction scheme is as follows:

pH 9-9 5
H 3 N —protein

protein

protein

0

II
(P -purine or pyrimidine; R is H or —P(OH)2)

The reaction involves oxidizing the ribose ring with periodate
to give a dialdehyde that couples to free amino groups.

‘The

resultant bond is stabilized by sodium borohydride, a reducing
agent.

(91)

Stollar and Borel modified this procedure for

linking nucleoside to sheep erythrocytes for use as target cells
in the hemolytic plaque assay (see below).

The modifications

consisted of the use of 0.15 M bicarbonate to maintain ionic
strength to prevent lysis and provide a suitable pH for Schiff
base formation, and the use of t-butylamine borane complex in
place of sodium borohydride, to prevent membrane damage during
reduction and to decrease reduction time (90).

To bind nucleo¬

side to lymphocyte membranes, further modifications were

.

20

necessary to prevent lymphoid lysis—namely5 to lower the pH
from 9o to 8.0 by adding an equal volume of MEM at physiological
pH to the 0.15 M bicarbonate buffer.
Variations were tried on the above method to attempt to
evaluate the binding and improve it if possible.

In addition to

the 80 x 10° cells bound to guanosine in the usual manner (MEM
at pH 8/ t-butylamine borane (Aldrich Chemical Co., Inc.,
Milwaukee, WI) ), Hank’s balanced salts solution (HBSS) (Micro¬
biological Associates, Walkersville, MA) was used in place of
MEM in an attempt to assess the effect of lowering the number
of free amino groups on binding and reduction by t-butylamine
borane.

Another group consisted of using MEM at physiological

pH to optimize conditions for cell viability.

The original

reducing agent sodium borohydride was used in place of tbutylamine borane in the final group.
The results shown in Fig. 1.
significantly.

All groups suppressed

The three groups exhibiting the most suppression

were the usual method, HBSS replacing MEM and NaBH^ replacing
t-butylamine borane.

Cell viabilities were 80 to 85$ for all

groups except for the group using NaBH^ which had 30$ viability.
Therefore, it appears that viable cells are not required for
generation of suppression in this system, confirming Claman and
Miller's results (75)-

Since the original method proved to be as

effective as the variations, no change was made in the basic
procedures of this project.

I
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FIG. i

The effect of varying conditions for the binding

of nucleoside on suppression of the immune response to G-KLH.
30 x 10° syngeneic spleen cells coupled to guanosine by
5 different conditions of binding, were injected i.v. into
groups of 5 BDF, mice with a group of untreated mice as
controls.

All mice were immunised on day 5 with 0.2 mg

G-KLH in CFA i.p.

Individual spleen suspensions were

made from each mouse on day 20 and assayed for PFC
against C— SRBC targets.

Each bar represents the

geometric mean of the group + s.e.

.
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INDUCTION OF SUPPRESSION
Animals were preheated under a heat lamp for vasadilatation.
Intravenous injections of cell suspensions were made with a 23
gauge needle via tail vein.

IMMUNIZATIONS
0.2 mg of C—KLH or AGCT-KLH in an equal volume of Complete
Freund's Adjuvant was injected per animal intraperitoneally.

(9*0

IN VITRO CULTURES
Spleen cell suspensions from either untreated C57BL/6
mice or C57BL/6 mice injected intravenously with 80 x 10^
guanosine-coupled spleen cells 7 days before, were cultured in
Marbrook-Diener tissue culture conditions in vitro (92).

Spleen

cells were challenged in vitro with guanosine^g-AECM-Ficoll
(gift of Dr. B. David Stollar) or sheep red cells, or without
antigen for evaluation of background.

Four days later, the

cells were harvested and assayed by PFC against either G-SRBC
or SRBC as target.

HEMOLYTIC PLAQUE ASSAY
The hemolytic plaque assay of Jeme (93) as modified by
Stollar and Borel (94) was used to assay the immune response
to the immunogen nucleoside-coupled KLH.

This is measured in

terms of number of plaque forming cells (PFC) making anti¬
nucleoside antibodies directed against nucleoside coated target
cells.

23.
Nucleoside-coupled sheep erythrocyte targets were prepared
by oxidizing nucleoside or tetranucleoside in the same manner as
described above for binding to lymphocytes.

SRBCs were washed

twice in 0.15 M bicarbonate buffer and 0.5 ml packed cells
was suspended in 2.0 ml 0.15 M bicarbonate buffer to make a
20^ suspension.

The cells were then added to the oxidized

nucleosides, binding for 15 minutes at room temperature, reduced
with 100 mg t-butylamine borane and washed three times with
0.15 M bicarbonate.
Animals were sacrificed and individual spleen suspensions
were made by expressing the tissue through surgical tantalum
gauze into 5 ml of MEM.

0.05 ml of the nucleoside-coated

SRBCs and 40 ul of the spleen suspension were added to 1 ml of
1% Agar (Difco Lab., Detroit, Mich.) in MEM, and the mixture

was poured In 60 x 15 mm tissue culture dishes (Falcon).

The

plates were incubated at 37° C. for one hour before 1 ml/ plate
of 1:30 diluted guinea pig complement (Cappel Laboratories,
Downingtown, PA) was added.

The plates were read after an

additional 45 minutes incubation at 37° C. for direct plaque
forming cells (PFC).

Indirect plaque forming cells were read

after incubating the plates with 1 ml/plate of 1:200 diluted
rabbit anti-IgG for an additional hour after reading direct PFC.
To obtain indirect PFC, direct PFC were subtracted from total
PFC read after incubating with anti-IgG.

No indirect PFCs were

observed in this system so they were not routinely done.

.
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STATISTICAL ANALYSIS
Statistical analysis was done according to Student's t
test for significance of difference in PFC numbers between groups.
The geometric means + standard errors were expressed,
was judged significant.

p <0.05

RESULTS

.
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BASIC SYSTEM
SUPPRESSION BY GUANOSINE-COUPLED SPIEEN CELLS
Preliminary experiments were done to establish whether
or not nucleoside-coupled spleen cells could induce suppression
of the animal's immune response to nucleoside-coupled KLH, a T
dependent antigen.

Guanosine was chosen to be the nucleoside

in these initial experiments because this nucleoside has been
shown to be immunodominant in the immune response to all four
nucleosides of DNA (94).

Groups of 5C57BL/6 male mice were

injected intravenously with varying doses of G-coupled spleen
cells (G-SC).

Control groups consisted of untreated mice or

mice injected with sham-modified spleen cells.

Five days

later, all animals were immunized with intraperitoneal injections
of 0.2 mg guanosine-KLH in complete Freund's adjuvant.

Direct

anti-guanosine plaque forming cells were assayed from individual
spleen suspensions using G-SRBC targets.

Suppression of

the

anti-guanosine PFC response was found to be dose-dependent
(Fig. 2).

6

The optimal dose was 80 x 10u G-coupied spleen cells;

increasing the dose had no additional effect on suppression.
80 x 10w sham-modified spleen cells did not suppress the anti-G
immune response at all.
KINETICS OF SUPPRESSION
The time course of suppression was then determined by
changing the length of time between the i.v. injection of Gcoupled spleen cells and the i.p. immunizing challenge with

g

G-KLH. Using the optimal dose of 80 x 10

guanosine-coupled

26.

Fig. 2

The dose response kinetics of suppression of the

Immune response to guanosine-KLH induced by intravenous
injection of guanosine-modified spleen cells.

Groups

5
of five C57B1/6 mice were injected i.v. with 80 x 10
G-couplea syngeneic spleen cells.

Five days later,

all mice together with a control group of five
untreated mice, were immunized
G-KLH in CFA.

i.p. with 0.2 mg

PFC against G-SRBC targets were

assayed on day 10.

Each point represents the

geometric mean of PFC per spleen i s.e. of each group
of 5 mice.

Statistical analysis by student's T Test.

PFC / SPLEEN

25

G-SC

x

1 o6

INJECTED

I.V.
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spleen cells, the time course of suppression was found to have a
short: latent period 24 to 48 hours after the i.v. injection,
to reach a maximum level of suppression when immunization was
done 5 days after i.v. treatment, and to be completely gone if
immunization was done 2 weeks later.

(Fig. 3)'

IN VITRO SUPPRESSION
The short latent period and the transience of suppression
is characteristic of many other systems (77 - 83, 87), and is
suggestive that this system like the others, involves T cell
mediated suppression.

To substantiate this, spleen cell
c

suspensions from C57BL/6 mice were injected i.v. with 80 x 10
G-coupled spleen cells, were cultured in vitro 7 days later and
challenged with a T independent antigen
SRBC or no antigen.

--AECM-Ficoll, with

Four days later, the cultures were

harvested and assayed for direct PFC to guanosine and SRBC.
The results in Table 1 show that the spleen cells of animals
treated with G-spleen cells could suppress the B cell response
to a T independent antigen, G-Ficoll.

The suppression is antigen

specific as shorn by the SRBC response, which was unchanged.

I
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Fig. 3

Kinetics of the suppression of the immune

response to guanosine-KLH.

Groups of five C57B1/6

g
mice were injected i.v. with 80 x 10
spleen cells on day 0.

G-coupled

Immunization of all mice

together with a control group of five untreated
mice, were immunized i.p. with 0.2 mg G-KLH in
CFA on varying days after i.v. treatment.

PFC

against G-SRBC were assayed five days later.
Each point represents

%

suppression of experimental

group from immune control group.

WITH

G-K LH

.
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SPECIFIC SUPPRESSION OF GUANOSINE IMMUNE RESPONSE
TO A T-INDEPENDENT ANTIGEN IN VITRO

TREATMENT OF MICE
BEFORE IMMUNIZATION
IN VITRO

antigen
target

NONE
80 x 10° G-SC i.v.

G-Ficoll
G-SRBC

SRBC
SRBC

P

550+176

5688+1216

56+129

-05 5557+1004

g
TABLE 1.

Spleen cell suspensions from either 80x10

G-SC i.v.

treated or untreated C57BL/6 mice cultured 7 days later in
Marbrook-Diener tissue culture conditions and challenged in vitro
with either Guanosine^o AECM-Picoll or SRBC or without antigen.
Cultures harvested after 4 days and assayed for PFC against
G-SRBC or SRBC targets.

Each figure represents the mean PFC of

four cultures + s.s. minus background.

PFC background to SRBC

was 12+63 and background to G-SRBC was 14+99-

Statistical

analysis was done according to Student’s t test.

.
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CM TETRANUCLEOSIDE BE SUPPRESSED?
The tetranucleoside (AGCT) was coupled to spleen cells of
either C57BL/6 or BDF^ mice and 80 x 10^ or 40 x 10^ AGCT-coupled
spleen cells were injected i.v. into syngeneic recipients.

Five

days later, these mice together with a control group of untreated
mice of the same strain, were immunized with tetranucleoside
coupled to KLH ( AGCT-KLH ).

The response to AGCT-KEH was

assayed by direct PFC to AGCT-SRBC targets.

The results (Fig. 4)

show almost identical suppression by the two strains to both doses
of AC-CT-SC.

SPECIFICITY OF SUPPRESSION
The specificity of the nucleoside tolerance system of Borel
is exquisite; when the animal is tolerized to guancsine with
guanosine-IgG2a .and subsequently immunised with AGCT-KLH, an
antibody response is produced to any nucleoside not conjugated
to the IgG carrier (90).

To assess the specificity of our

nucleoside suppression systems, groups of five C57BL/6 mice were

g

suppressed with 80 x 10
AGCT-KLH on day 5*

guanosine-SC i.v. and challenged with

To ascertain if the animals were responding

with just anti-G or anti-AGCT or other antibodies, a panel of
5 differently coupled SRBC targets was provided:

AGCT-SRBC,

A-SRBC, C— SRBC, C-SRBC and T-SRBC, for assay on day 10.

For

comparison, a group was tolerized to C- with G-IgG2a; control
groups consisted of mice that received 80 x 10° sham-modified
SC and an untreated group.

.
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Fig. 4

Comparative suppression of the immune

response to AGCT-KLH induced by syngeneic
AGCT-KLH induced by syngeneic AGCT-Modified spleen
cells in C57B1/6 and BDF mice.

Groups of five

mice of each strain were treated i.v. with
30 x 10

f)

ft

arid 40 x 10° syngeneic AGCT-modified

spleen cells.

Lmmunization with AGCT-KLH

and PFC against AGCT-3RBC targets were
performed similarly as described in Fig. 2.
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TABLE 2.
G-SC.

Groups of C57BL/6 mice were treated i.v. 80 x 10^

Controls consisted of an untreated group, a group

g
receiving 80 x 10

sham-modified SC, and a group made tolerant

to G with 0.2 mg G-IgG2a.

All mice were Immunized i.p. 5 days

later with 0.2 mg AGCT-KLH in complete

Freund's Adjuvant

Animals were sacrificed on day 10 and individual spleen cell
suspensions were made and assayed for direct PFC against
targets coated with 'AGCT as well as targets coated with A, G,
C, T individually.
spleen + s.e.

Values are geometric means of PFC per

33.

The immune response of these G-SC treated animals to SKBC was
also examined.

The results show that treatment with C—SC

affects not only the immune response to the hapten on the
modified lymphoid cell i.e. guanosine, but also the immune
responses to adenosine and cytosine as well.

In contrast,

tolerance induced by G-IgG2a was specific for guanosine.

'Thus,

the specificity of suppression induced by G-coupled SC is
broader than the tolerance induced by G-IgC-2a.

The suppression

was specific for nucleosides, however, as the immune response
to SRBC, an unrelated antigen, was unaffected in vivo.

(PFC

to SRBC = 158,700 - 30,200 in G-SC treated mice five days before
challenging with 0.1 ml of 20% SRBC suspension, and PFC =
158,600 - 21,500 in ’untreated mice similarly challenged.)

ROLE OF 'THE CELL CARRIER
Thus far in our system, the spleen cell seems to be a very
effective cellular carrier for hapten-specific tolerance.

The

next experiment varied the cell carrier in an effort to discover
whether any other cell type might serve as an optimal carrier
for nucleosides.

The results are shown in Fig. 5-

Syngeneic

splenocytes 'were the most effective carriers for suppression;
thymus cells induced significant suppression but only half as
well as splenocytes.

Syngeneic and xenogeneic erythrocytes

were ineffective carriers of nucleoside suppression.

FIG. 5

The role of the cell carrier in suppression of

the immune response to AGCT-KLH.

80 x 10

cells of

different types were coupled to AGCT and injected i.v.
into groups of 5 C573L/6 mice.

All mice together with

a control group of untreated mice were immunised 5 days
later with 0.2 mg AGCT-KLH in CFA i.p.

PFC against

AGCT-SRBC targets were assayed on day 10.

Each bar

represents the geometric mean of each group + s.e.

o

CONTROL

AGCT-SC

AGCT-TC

AGCT-MRBC

AGCT-HRBC

.
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STRAIN DIFFERENCES IN NUCLEOSIDE SUPPRESSION
All the data presented have been in the C57BL/6 and the
BDFn strains.

Interestingly, the comparative data between

the parent and the F^ with regard to AGCT-airected suppression
were very similar.

(Fig. 4)

The next question asked concerned

whether there existed any strain differences in the generation
of suppression and whether there existed any strains which
were resistant to suppression with nucleosides.

'The DBA/2

(the other parental strain of the BDF^), the SJL/J and the
BALB/c were tested, using the dose of 80 x 10° spleen cells
coupled to AGCT and administered i.v. into syngeneic recipients.
The results are presented in Fig. 6.

All strains could be

suppressed except for the SJL/J which did not exhibit
significant suppression.
The final experiment to be presented represents the
natural endpoint for the techniques generated by this system—
namely, the investigation of T cell suppression'in the New
Zealand mice: the New Zealand Black (NZB), the New Zealand
White (NZW) and the (NZB X NZW)F^ or the BWF^.

This system

would enable the investigation of the current notion that
the pathogenesis of autoimmunity in the NZB/W mice is due to
loss of suppressor cell activity with age allowing forbidden
clones of lymphocytes with autoantigen specificity to develop

(58,111).

.
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FIG. 6

Strain differences in the suppression of the

immune response to AGCT-KLH3 induced by syngeneic AC-CTcouplea spleen cells.

^ represents immune controls, i

represents suppressed response.

80 x 10° AGCT-coupled

syngeneic spleen cells were injected i.v. into groups
of five mice.

Five days later, all mice were immunized

with 0.2 mg AGCT-XLH in CFA i.p.

PFC against AGCT-

SR5C targets we re assayed on day 10.

Each bar represents

the geometric mean of each group + s.e.

P FC X 10

per S PLEE N

.
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Relatively young (8-12 weeks) male NZB mice and 6 week
old male BWF, mice were injected i.v. with 80 x 10^ AGCT-coupled
syngeneic spleen cells and immunized on day 5 with 0.2 mg
AGCT-KLH per usual.

The result is shown in Fig. 7-

degree of suppression in both strains was observed.

A high

.
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. 7

The suppression of the immune response

AGCT-KLH induced by syngeneic AGCT-coupled
een cells in 8 to 10 week old MZE male mice
5 week old BWF, male mice.

N Z B

AG C T - S C

B W F

i. v.

1

DISCUSSION

.
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Suppression induced by a variety of haptens presented on
cells has been extensively investigated as reviewed above.

In

this thesis is presented a new model of suppression directed
against the immune response to nucleosides, naturally occurring
haptens which are components of nucleic acids.

Suppression to

nucleosides is cell dose dependent, requires a latent period
to develop and has transient kinetics.

Suppression was induced

against both a T dependent antigen in vivo and a T independent
antigen in vitro; this together with the kinetic profile is
strongly suggestive of T cell mediated suppression.

Anti¬

nucleoside suppression is antigen-specific but lacks the
exquisite specificity of carrier-induced tolerance.

Except

for SJL/J mice, anti-nucleoside suppression was demonstrated
in all strains of mice tested including the NZB and BWF- mice.
Preliminary data show that the spleen cell is the most effective
cell carrier for suppression and suggests that there is an
H-2 requirement for anti-nucleoside suppression.
In this model of anti-nucleoside suppression, nucleosides
are coupled directly to cells by covalent bonding to membrane
proteins.

This coupling is stable after reduction.

There

is no secondary binding of the nucleoside in vivo once this
coupling has occurred.

Whether the resultant nucleoside-

membrane complex is catabolized and/or pinocytosed is not
known.
After covalent conjugation, the nucleoside-modified cells
were injected intravenously into syngeneic mice.

A humoral

.
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immune response was then Induced by the intraperitoneal immuniza¬
tion of nucleoside conjugated KLH.

Suppression of the anti-

nucleoside response was assayed by hemolytic plaques 5 days
after immunization.

Significant suppression was observed for

both guanosine and for the tetranucleoside AGCT.

The optimal

conditions for suppression with nucleoside-coupled spleen cells

g

was found to be a dose of SO x 10

nucleoside conjugated spleen

cells injected i.v. 5 days prior to immunization.

The kinetics

of suppression showed that the phenomenon is transient, requiring
a latent period of 24-48 hours, reaching a peak after 5 days
and disappearing by 2 weeks.
The transience of this anti-nucleoside suppression is
similar to the transience found in other systems of suppression

shown to be mediated by suppressor T cells (77,82,83,87,95)The latent period and transient kinetics of these systems
presumably represent the Induction and differentiation of
suppressor T cells, an active process requiring DNA synthesis.

Indeed, Miller, et al. (77) and Scott (84) found that the
suppressor mechanism in their system was cyclophosphamide
sensitive.

These kinetics are hypothesized by Naehtigal, et al.

(99) as being due to the short functional life span (approximately
14 days) of immature suppressor cell precursors.
describes the immature T

s

Their model

as either dying within 2 weeks or

differentiating into a mature stage after which differentiation
into suppressor cells was no longer possible (10).

This model

was based on experiments in which adult thymectomised mice

41.
were able to be tolerized and produce specific T , only up
s
until 14 days after thymectomy.
unable to produce T

s

After 14 days, the mice were

presumably because the pool of thymic T

s

precursors was exhausted (10).
Suppression was induced to the immune response against
both a T dependent antigen (KLH) in vivo and to a T independent
antigen (Ficoll) in vitro.

This, together with the kinetic

profile of nucleoside suppression is consistent with a suppressor
T cell system.

Furthermore, much work on the mode or route

of administration of haptenated cells by Benacerraf, et al. and
others, (82,86) has established that intravenous administration
preferentially stimulates suppressor responses.

While the

same cell preparation adminsterea subcutaneously results in
delayed type hypersensitivity (82,86), the simultaneous adminis¬
tration of cells by both routes preferentially generates
suppressor T cell responses and suppress the development of
contact sensitivity (82).

The reason for this phenomenon

might be the lymphoid tissues the injected cells first encounter:
intravenously injected cells tend to localize in the spleen
while subcutaneously injected cells localize in lymph nodes (86).
Rich, et al. (103) found that after sensitization, spleen cells
suppressed MLR responses while lymph node cells enhance MLH.
Sy, et al.

(100) demonstrated a splenic requirement for

induction of suppressor T cells: splenectomy before administra¬
tion of DNFB did not result in T .
s

The spleen was found to be

required at least 3 days after tolerization.

.
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The results presented in this thesis are suggestive of
T

s

involvement but do not definitely prove it.

Conclusive

proof showing abrogation of suppression with treatment with
anti thy 1-2 and complement in vitro as well as demonstration
of nylon wool enrichment of suppression, are currently in
progress.

Other experiments planned to further substantiate

suppressor T cell involvement include adoptive transfer of
splenocytes from mice suppressed with 80 x 10^ AGCT-SC 5-7 days
prior to transfer, as well as in vitro studies of the effects
of culture supernatants or cell-free extracts on suppression.
Hopefully, these data will further elucidate the cellular and
biochemical mechanisms of this system.
From the results presented above, it appears that there
now exists 2 different techniques for inducing immunological
unresponsiveness to nucleosides, the carrier-induced toleranced
mechanism described by Borel and Stollar (116) using nucleoside
coupled to isologous gammaglobulin and the suppression induced
by nucleoside coupled to syngeneic lymphoid cells.

The

mechanisms of "tolerance" and "suppression" are presumably
different.

Presenting hapten on soluble protein carriers

results in tolerance through receptor blockade of B cells (117).
This model postulates that B cells are rendered unresponsive
i.e. tolerant, when

their antigen receptors are reversibly

occupied by the hapten-carrier conjugate (97).

Presenting

hapten on cell surfaces results in the generation of a clone
of antigen-specific suppressor T cells (75,78,79,86).

The

.
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precise mechanism of this process is not known.
explanation may be that the T

s

A possible

receptor recognize larger

determinants e.g. membrane bound hapten, as opposed to the smaller
complex of protein-coupled hapten recognized by B cells.

It

is well established that antigen cross-reactivity at the T cell
level is broader than at the antibody level (llS).

This

difference in cross-reactivity between the T cell receptor and
the B cell receptor could account for the exquisite specificity
of B cell anti-nucleoside tolerance and the somewhat broader
specificity observed for presumed anti-nucleoside T cell
suppression.
The mechanism of T cell mediated suppression in the DNFB
and the picryl chloride (TNCB) contact sensitivity systems has
been extensively investigated and it is now known that

can

inhibit either the early cell proliferative phase of contact
sensitivity (the afferent limb of sensitization) or inhibit
the expression of immune effector cells (the efferent limb of
sensitization).
antigens induce

It is of interest that different haptens /
that inhibit different limbs of sensitization.

Cell proliferation has been shown to be the target of T

in the
O

suppression of DNFB contact sensitivity (26,119), suppression
of MLC responses (120,121), and responses to type III pneumo¬
coccal polysaccharide (122).

Inhibition of the efferent limb

or expression of an immune response has been demonstrated for
picryl chloride contact sensitivity (22), DNFB contact sensitivity
(25) and response to tumor antigens (123).

It is interesting
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that the difference of one nitro group (DNFBvs picryl chloride)
results in a comolete alteration of the mechanism of T

s

suppression.
Miller, et al. have recently shorn in the DNFB contact
sensitivity system, that the suppressor T cells induced by
syngeneic DNP-coupled lymphoid cells (syninduced T ) selectively
s
block the efferent limb of sensitivity by inhibiting the expres¬
sion of lymph node cells from sensitized animals (25).

Co¬

transferred syninduced Tg block the passive transfer of contact
sensitivity to normal recipients.

Syninduced T„ did not affect

the afferent limb of sensitization and are not H-2 restricted.
In contrast. Miller, et al. found that the afferent limb was
selectively inhibited by T

2

induced by allogeneic DNP-coupled

lymphoid cells (alloinduced T ) leaving the efferent limb
•D

unaffected (26).

The target of alloinduced T

s

appears to be

cell proliferation as measured by DNA synthesis.
of alloinduced T

Recipients

fail to generate immune lymph node cells
O

capable of transferring contact sensitivity to normal animals.
The suppression by alloinduced T

s

appears to be H-2 restricted.

It is possible that the roles of afferent and efferent blockade
in suppressor cell regulation are different: afferent blockade
may serve to maintain self-tolerance while efferent blockade
may serve to limit clonal expansion after normal immune
responses have gotten under way (26).

The mechanism of our

model of anti-nucleoside suppression has not been dissected
sufficiently to determine the precise site of T„ action.

.
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The mechanism of action of suppressor T cells has been
found to be mediated by soluble factors in many systems of
suppression.

Tada et al. (11) characterized an antigen-specific

suppressor factor from mice immunized with KLH as smaller than
immunoglobulin and containing antigens coded for by the I-J
region of the major histocompatability complex (MHC).

Kapp and

Benacerraf (123) isolated a very similar soluble factor from
nonresponder mice primed with GAT which differed in being less
MHC restricted in action.

Asherson and Zembala (22) described

a suppressor factor specific for the picryl chloride contact
sensitivity system.

It bears H-2 determinants and is selective

for the efferent limb of contact sensitivity.

The soluble

factor isolated for the DNFB contact sensitivity system is
also selective for the efferent limb and is H-2 restricted
(24,125)*

The most recently characterized antigen-specific

suppressor factor by Taussig, et al. (114) was described in the
introduction of this thesis.

A number of non-antigen specific

factors have also been well characterized.

Pierce and Kapp

isolated a soluble immune response suppressor (SIRS) from CcnAinauced T
(6).

cells which suppress PFC responses non-specifically

It does not contain antigens coded by by MHC and has

many biochemical similarities to MIF.

Rich and Rich isolated

a non-specific suppressor factor secreted dining mixed lympho¬
cyte reaction (126).

Tnis factor bears MHC antigens coded for

by the I-C region, and is MHC restricted in action.

.
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The isolation of nucleoside-specific suppressor factor from
the anti-nucleoside suppression model would be useful in several
ways.

It would first substantiate the involvement of Tg cells in

the system.

It would also allow us to test whether or not suppres¬

sion of anti-nucleoside antibody can be suppressed without the use
of cell bound hapten in vivo.

The outcome of this experiment

could be significance for new modes of therapy In systemic lupus
and other disorders thought to involve T cell suppression.
The syngeneic splenocyte was found to be the most effective
carrier for suppression of anti-nucleoside.

This is consistent

with other models of suppression (77,82,83) confirming the potency
of hapten-coupled lymphoid cells as ”tolerogenM.
suppressed significantly also,

AGCT-thymocytes

Syngeneic erythrocytes and

xenogeneic (horse) erythrocytes did not suppress significantly
from the control response,

The results suggest that the presence

of H-2 antigen might be required on the carrier cell surface in
order for suppressor T cells to be generated: thymocytes have
approximately one fourth the amount of H-2 antigens on spleen
cells, and erythrocytes have virtually no H-2 antigen on the
membrane (104),

This H-2 requirement is consistent with the H-2

requirement well-established for T cell mediated cytotoxicity (105,106)
and for some but not all systems of T cell mediated suppression
(78,79,84).

Further experiments using H-2 incompatible spleen

cell from allogeneic strains or H-2 negative cells from tumor
cell lines e.g, teratoma cell lines as carriers will be needed to
substantiate the H-2 requirement.
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The interesting point to consider here is that while no
suppression was generated in the nucleoside system by haptenated
syngeneic erythrocytes, suppression was evident in other systems
(81,87,95,107,108).

The hapten used in these other systems was

either TNP or DNP and it is possible that the cell surface bound
with nucleoside is less tolerogenic than when bound with these
compounds.

An alternative explanation might simply be that the

nucleoside system is hT-2 restricted whereas the other systems
are not.

Further experiments are in progress to examine the

effectiveness of administering nucleoside-coupled macrophages,
lymph node cells, bone marrow cells, and purified B and T cells.
Long and Scott (83) found that thymocytes were "marginally
effectiveM in

tolerogenecity, and B cells and bone marrow cell

were ineffective.
Using the data for optimal suppression in the C57BL/6 and
BDF^ strains, i.e. 80 x 10^ ACtCT-SC i.v. followed by immunization
on day 5, several inbred strains were examined for capacity to
generate suppression.

All the strains examined: C57BL/6J,

DBA/2, BDF^, (C57BL/6J x DBA/2)F1, BALB/C could generate
suppression except for SJL/J, which did not have significant
suppression.

It is interesting that SJL are high responders

to nucleoside antigens (110) and fail to suppress, while BALB/C
are low responders and suppress very well C109).
that SJL lack a T

s

It is possible

clone for regulating the response to nucleic

acids, hence decreasing the capacity to generate suppression.
There may be other host factors peculiar to SJL involved.

SJL

mice were recently found to have age-dependent loss of suppressor

.
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ability (111).
generate T

An interesting study will be to attempt to

in SJL with AGCT-BALB/C SC, to do the same in BALB/C

with AGCT-SJL SC, and to raise suppression in the (BALB/C X SJL/J)
F^ with AGCT-coupled to parental strain SC.
Two findings of this research project are of direct relevance
to SLE: 1) the successful generation of suppression in young NZB
male mice and BWF, male mice and 2) the specificity of suppression
induced by G-SC is broader than the specificity of tolerance
induced by G-IgG.
The age dependent loss of suppressor T cell in NZB and NZB/
NZW F^ (BWF^) mice has been reported occurring between 1 and 2
months of age, according to thymocyte proliferation and antigeninduced suppression assays (112).

It is thus very important that

suppression was successfully generated in these 8-12 week old mice
showing that there is no genetic inability of NZB and BWF,, mice to
generate T^ to nucleosides.

Possessing a system of suppression

directed against an antibody thought to be the cause of tissue
damage in SLE will allow us to test the hypothesis that the
pathogenesis of SLE is due to the loss of suppressor T cells.
Experiments on the NZW and BWF, are in

progress and can reveal

relevant information on the possible genetic defects in suppression.
Sex differences in the generation of suppression will also be
examined.

If suppressor cells can be successfully generated, it

will be important to assess the resultant effect on anti-DNA
production as well as the ensuing clinical course of murine lupus.
The finding that the specificity of T cell suppression is

.
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broader than B cell mediated tolerance has obvious therapeutic
implications for murine lupus.

If oligonucleotides could be

coupled to lymphocytes, the resultant suppression could have
specificity broad enough to include not just anti-oligonucleotide
but antibodies to all nucleic acids including native DMA and RNA.
The broad amplications of the nucleoside suppression model
in the NZ mice are enormous and will hopefully reveal not only
possible therapeutic regimens for human SLE, but elucidate basic
cellular mechanisms of Immunologic regulation and tolerance.
The basic system of inducing suppression to nucleoside
antigens gives us a tool to explore many new areas and
happily generates more questions than answers.
immune response to nucleosides be suppressed?
response to nucleosides be suppressed?

Can an ongoing
Can a secondary

Can cell mediated immunity

i.e. cytotoxic ,Tkiller’T cells or delayed hypersensitivity to
nucleoside antigens be generated?

What is the effect of suppression

induction on the production of anti-DMA?
the major histocompatability

What is the role of

complex in autoimmune disease?

Hopefully, the answers to these questions and the Important
questions related to SLE can be found using the techniques generated
in this model.

SUMMARY

.
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A new model of suppression is presented in which suppressor
cells to autoantigens i.e. nucleosides have been generated in
vivo and in vitro in mice.

This was done by covalent coupling

of the four nucleosides of DNA to lymphoid cells.

The

following observations were made:
1)

The suppression is dose dependent, requires a latent
period to develop and is transient.

2)

Anti-nucleoside antibody forming cells to both T
dependent and T independent antigens were suppressed.

3)

The suppression is antigen-specific but the
specificity of suppression (induced by nucleosidecoupled cells) is broader than the specificity of
tolerance (induced by nucleoside-coupled gammaglobulin).

4)

Anti-nucleoside suppression appears to require H-2
antigen on the cell carrier.

5)

Suppression of anti-nucleoside antibody can be
generated in a variety of strains of mice except for
the SJL/J strain.

6)

NZB and BWF, mice have the ability to generate
suppression to anti-nucleoside antibody,

This model of suppression is significant for the study of
systemic lupus because 1) it will allow us to test the hypothesis
that the pathogenesis of this disorder is due to the loss of
suppressor cells, and 2) the ability to generate nucleosidespecific suppressor cells may prove to be a tool in the treatment
of SIE.
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